Navigation Links
Cardium Reports on Second Quarter 2008 Highlights and Financial Results
Date:8/11/2008

involve a variety of risks and uncertainties, many of which are beyond our control and may cause actual results to differ materially from stated expectations. For example, there can be no assurance that human clinical trials can be conducted and completed in an efficient and successful manner, that product modifications or launches will be successful or that the resulting products will be favorably received in the marketplace, that results or trends observed in one clinical study or procedure will be reproduced in subsequent studies or procedures, that our products or product candidates will prove to be sufficiently safe and effective, that necessary regulatory approvals will be obtained, that third parties on whom we depend will perform as anticipated, or that our products or product candidates will not be unfavorably compared to competitive products that may be regarded as safer, more effective, easier to use or less expensive. Actual results may also differ substantially from those described in or contemplated by this press release due to risks and uncertainties that exist in our operations and business environment, including, without limitation, risks and uncertainties that are inherent in the development of complex biologics and therapeutic hypothermia devices and in the conduct of human clinical trials, including the timing, costs and outcomes of such trials, our ability to obtain necessary funding, regulatory approvals and expected qualifications, our ability to successfully accelerate the commercialization of our therapeutic hypothermia devices and launch new devices within the timeframes contemplated, our dependence upon proprietary technology, our history of operating losses and accumulated deficits, our reliance on collaborative relationships and critical personnel, and current and future competition, as well as other risks described from time to time in filings we make with the Securities and Exchange Commission. We undertake no obligation to release pu
'/>"/>
SOURCE Cardium Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Cardium Announces Appointment of Paul A. Foster, M.D. to Lead Generx and Excellarate Late-Stage Development Activities
2. Cardiums Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack
3. Cardium and Tissue Repair Companys Excellarate Candidate for Healing Diabetic Wounds Gains Media Focus in Multiple Regions Across U.S.
4. Nature Publication Reports on Key Role of Bile Acids in Glucose Metabolism and Insulin Signaling
5. Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates
6. Isolagen, Inc. Reports Positive Top-line Results from Pivotal Phase III Studies of Isolagen Therapy(TM) in Wrinkles: Studies Meet All Primary Efficacy Endpoints and are Statistically Significant
7. Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
8. CuraGen Reports Second Quarter 2008 Financial Results and Clinical Progress of CR011-vcMMAE
9. BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting
10. Bioheart Reports Promising Results From SDF-1 Modified MyoCell(R) Therapy in Heart Failure Study
11. Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacells ONCONASE(R) and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... BOTHELL, Wash. , Sept. 23, 2014   ... a leading developer, manufacturer and marketer of proprietary clinical ... media and precision thermal shipping products ... announced two new additions to its Scientific Advisory Board.  ... and Anthony Davies , PhD. Dr. ...
(Date:9/22/2014)... BARCELONA, Spain , September 23, 2014 ... sponsors to meet health authorities, increasing rigor for trial ... The life sciences industry,s largest TMF survey to date ... sponsors that plan to provide auditors with remote access ... 32% of TMF owners surveyed in the ...
(Date:9/22/2014)... NEW YORK , Sept. 22, 2014 /PRNewswire/ ... is in mature stage. It is largely a ... endoscopy suite expansion. The mergers, acquisitions and partnerships ... Europe . This research service provides details ... competitive environment and pricing trends across the country. ...
Breaking Medicine Technology:BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 2BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 3BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 4BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 5BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 6BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 7Remote eTMF Access to Double in 2015, Reveals Industry-wide Survey 2Remote eTMF Access to Double in 2015, Reveals Industry-wide Survey 3Remote eTMF Access to Double in 2015, Reveals Industry-wide Survey 4Automated Endoscope Reprocessor Market Trends in Western Europe 2Automated Endoscope Reprocessor Market Trends in Western Europe 3
... RoundTable Healthcare Partners ("RoundTable"), an operating-oriented private equity ... today that it has entered into a definitive ... Clinical Innovations, LLC ("Clinical"), to The Pritzker Group, ...  Terms of the transaction were not disclosed. ...
... Amira Pharmaceuticals, Inc. announced today that it has ... lysophosphatidic acid (LPA)-related program, autotaxin.  Autotaxin is an enzyme ... a number of diseases including rheumatoid arthritis, glioblastoma, lung, ... pleased to announce that we have identified an orally ...
Cached Medicine Technology:RoundTable Healthcare Partners Announces Sale of Clinical Innovations, LLC to The Pritzker Group 2Amira Pharmaceuticals Announces the Nomination of an Orally Available Pre-Clinical Candidate in a New LPA-Related Program, an Autotaxin Inhibitor 2
(Date:9/23/2014)... better screening strategies can lower the rate of false-positive ... on women. The many misperceptions about breast cancer screening ... and the need for new approaches and better education ... supplement to Journal of Women,s Health , a ... supplement is available free on the Journal of ...
(Date:9/23/2014)... National Institutes of Health has awarded $10.1 million in ... to explore the effects of sex in preclinical and ... females and males, and is a catalyst for considering ... overreliance on male subjects in preclinical research can obscure ... human studies. This progressive approach will result in greater ...
(Date:9/23/2014)... BLOOMINGTON, Ind. -- Contrary to what is often assumed ... a new study from The Kinsey Institute has found ... and are sexually active as often as singles without ... older children. , The study, "Dating and Sexual Behavior ... States," was published online in the Journal of ...
(Date:9/23/2014)... 2014 PM360, a leading health-marketing industry ... industry with their annual Trailblazer Awards on Thursday, September ... at Gotham Hall in New York City, are given ... talent and brands. , “This industry ... Stashower, CEO and Publisher of PM360. “We are happy ...
(Date:9/23/2014)... 2014 The University of Maryland Medical System ... Court to pay $3 million for negligence during the delivery ... anterior arm [shoulder dystocia occurs after the delivery of the ... mother’s pelvic bone]. , On September 5, ... Uriah Evans, et. al. v. University of Maryland Medical Systems ...
Breaking Medicine News(10 mins):Health News:Opportunities to reduce patient burden associated with breast cancer screening 2Health News:New supplemental awards apply sex and gender lens to NIH-funded research 2Health News:New supplemental awards apply sex and gender lens to NIH-funded research 3Health News:Kinsey study of single parents' dating, sexual activity contradicts assumptions 2Health News:PM360 Magazine Announces Winners of 2014 Trailblazer Awards 2Health News:PM360 Magazine Announces Winners of 2014 Trailblazer Awards 3Health News:PM360 Magazine Announces Winners of 2014 Trailblazer Awards 4Health News:PM360 Magazine Announces Winners of 2014 Trailblazer Awards 5Health News:PM360 Magazine Announces Winners of 2014 Trailblazer Awards 6Health News:Toddler Awarded $3 Million in a Shoulder Dystocia Case Against University of Maryland Medical System with Help from Attorneys at Gilman & Bedigian LLC 2Health News:Toddler Awarded $3 Million in a Shoulder Dystocia Case Against University of Maryland Medical System with Help from Attorneys at Gilman & Bedigian LLC 3
... a boost from a surprising source: the 2009 H1N1 pandemic ... strain developed antibodies that are protective against a variety of ... the University of Chicago have found. The results were published ... "Our data shows that infection with the 2009 pandemic ...
... , , Reproductive medicine is one of ... there are announcements of medical ,firsts, new rulings by ... heated debate among practitioners in the field, ethicists, legislators, ... is the forum where more than 9,000 of the ...
... News) -- Race and ethnicity play major roles in whether ... with minorities much less likely to undergo colonoscopies than white ... play: where people live. Research by oncologist Dr. ... Davis Cancer Center found that location makes a big difference ...
... January 10, 2011 -- While most blood tests require shipping a ... days for the results, a new device invented by a team ... just a pinprick of blood in a portable device that provides ... big step in point-of-care diagnostics, where testing can be performed in ...
... News) -- The first study to focus solely on the ... Sept. 11, 2001 attacks on the World Trade Center finds ... of the 3,271 evacuees of the Twin Towers surveyed in ... at least one current post-traumatic stress symptom, while 15 percent ...
... be most useful for clinical decision-making in trials in which ... recent study published online January 7 in The ... has been increasing interest in the value of patient-reported symptom ... secondary endpoints in new trials. Both the World Health Organization ...
Cached Medicine News:Health News:Pandemic flu strain could point way to universal vaccine 2Health News:Pandemic flu strain could point way to universal vaccine 3Health News:ESHRE bridges East and West for its 2012 Congress in Istanbul 2Health News:Geography May Influence Colon Cancer Screening Rates 2Health News:Engineering team invents lab-on-a-chip for fast, inexpensive blood tests 2Health News:Many Survivors of World Trade Center Attacks Suffered PTSD: Study 2Health News:Quality of life measures in breast cancer clinical trials 2
Inquire...
Protects the skin over extended wearing time from irritating discharge. Flextend skin barrier is the barrier of choice for urostomies and ileostomies with the added benefit of it being discreet in bo...
Inquire...
Inquire...
Medicine Products: